Rundquist L, Lyons S, Moljo R, Blavo C
Cureus. 2025; 17(1):e77101.
PMID: 39917160
PMC: 11802192.
DOI: 10.7759/cureus.77101.
Yadav V, Dhanasekaran S, Choudhary N, Nathiya D, Thakur V, Gupta R
Front Med (Lausanne). 2025; 12:1535682.
PMID: 39911864
PMC: 11794224.
DOI: 10.3389/fmed.2025.1535682.
Zhao Z, Fu Q, Guo X, He H, Yang G
Actas Esp Psiquiatr. 2025; 53(1):181-188.
PMID: 39801407
PMC: 11726199.
DOI: 10.62641/aep.v53i1.1779.
Xu J, Dai P, Zhang C, Dong N, Li C, Tang C
Adv Sci (Weinh). 2024; 12(4):e2412020.
PMID: 39630931
PMC: 11775539.
DOI: 10.1002/advs.202412020.
Sun P, Li J, Shen H, Jiang Y, Wang X, Xu T
Medicine (Baltimore). 2024; 103(48):e40689.
PMID: 39612411
PMC: 11608732.
DOI: 10.1097/MD.0000000000040689.
Inter-rater reliability of hand motor function assessment in Parkinson's disease: Impact of clinician training.
Kenny L, Azizi Z, Moore K, Alcock M, Heywood S, Johnson A
Clin Park Relat Disord. 2024; 11:100278.
PMID: 39552791
PMC: 11566327.
DOI: 10.1016/j.prdoa.2024.100278.
Efficacy and safety of safinamide in Parkinson's disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study.
Oh E, Cheon S, Cho J, Sung Y, Kim J, Shin H
J Neural Transm (Vienna). 2024; 132(3):431-441.
PMID: 39540934
PMC: 11870872.
DOI: 10.1007/s00702-024-02851-6.
The Influence of Dopaminergic Medication on Regularity and Determinism of Gait and Balance in Parkinson's Disease: A Pilot Analysis.
Workman C, Thrasher T
J Clin Med. 2024; 13(21).
PMID: 39518623
PMC: 11546099.
DOI: 10.3390/jcm13216485.
Novel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease.
Kumar A, Gupta A, Singh P
AIMS Neurosci. 2024; 11(3):312-340.
PMID: 39431269
PMC: 11486614.
DOI: 10.3934/Neuroscience.2024020.
A Comprehensive Review on Repurposing the Nanocarriers for the Treatment of Parkinson's Disease: An Updated Patent and Clinical Trials.
Khan S, Haider M
CNS Neurol Disord Drug Targets. 2024; 24(3):181-195.
PMID: 39400019
DOI: 10.2174/0118715273323074241001071645.
Levodopa-induced dyskinesia: brain iron deposition as a new hypothesis.
Zhang F, Ye Z, Xie Y, Liu M, Zhang L, Zhang J
Biometals. 2024; 37(6):1307-1323.
PMID: 39212870
DOI: 10.1007/s10534-024-00628-8.
Drug Development for Alzheimer's and Parkinson's Disease: Where Do We Go Now?.
Sequeira L, Benfeito S, Fernandes C, Lima I, Peixoto J, Alves C
Pharmaceutics. 2024; 16(6).
PMID: 38931832
PMC: 11206728.
DOI: 10.3390/pharmaceutics16060708.
Bidirectional regulation of levodopa-induced dyskinesia by a specific neural ensemble in globus pallidus external segment.
Shen C, Shen B, Liu D, Han L, Zou K, Gan L
Cell Rep Med. 2024; 5(6):101566.
PMID: 38759649
PMC: 11228392.
DOI: 10.1016/j.xcrm.2024.101566.
What was first and what is next in selecting device-aided therapy in Parkinson's disease? Balancing evidence and experience.
Phokaewvarangkul O, Auffret M, Groppa S, Markovic V, Petrovic I, Bhidayasiri R
J Neural Transm (Vienna). 2024; 131(11):1307-1320.
PMID: 38747986
DOI: 10.1007/s00702-024-02782-2.
Motor Complications in Parkinson's Disease: Results from 3343 Patients Followed for up to 12 Years.
Gandhi S, Zerenner T, Nodehi A, Lawton M, Marshall V, Al-Hajraf F
Mov Disord Clin Pract. 2024; 11(6):686-697.
PMID: 38587023
PMC: 11145112.
DOI: 10.1002/mdc3.14044.
Unraveling the interplay between dyskinesia and overactive bladder symptoms in Parkinson's disease: a comprehensive cohort study based on the long-term follow-up database of Parkinson's disease.
Jin H, Du Y, Yan J, Zhang J, Cheng X, Mao C
BMC Neurol. 2024; 24(1):94.
PMID: 38468238
PMC: 10929158.
DOI: 10.1186/s12883-024-03578-3.
The Interplay of Mitochondrial Bioenergetics and Dopamine Agonists as an Effective Disease-Modifying Therapy for Parkinson's Disease.
Neha , Mazahir I, Khan S, Kaushik P, Parvez S
Mol Neurobiol. 2024; 61(10):8086-8103.
PMID: 38468113
DOI: 10.1007/s12035-024-04078-8.
Advanced Parkinson's disease treatment patterns in Italy: an observational study interim analysis.
Stocchi F, Barone P, Ceravolo R, De Pandis M, Lopiano L, Modugno N
Ann Med. 2024; 56(1):2315226.
PMID: 38381654
PMC: 10883087.
DOI: 10.1080/07853890.2024.2315226.
Dyskinesia and Pain in Advanced Parkinson's Disease: Post Hoc Analysis from the Phase 3b, Open-Label, Randomized DYSCOVER Study.
Freire-Alvarez E, Vanni P, Kurca E, Lopez-Manzanares L, Kovacs N, Spanaki C
Neurol Ther. 2024; 13(2):437-447.
PMID: 38345741
PMC: 10951158.
DOI: 10.1007/s40120-024-00583-z.
Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline.
Hattori N, Kabata D, Asada S, Kanda T, Nomura T, Shintani A
PLoS One. 2023; 18(12):e0269969.
PMID: 38134023
PMC: 10745149.
DOI: 10.1371/journal.pone.0269969.